Drug Trial Radar · NCT06467344
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 11, 2024
Primary completion
Aug 1, 2030
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Ascidian Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Conditions
- Stargardt Disease
- Cone Rod Dystrophy
- Juvenile Macular Degeneration
- Stargardt Disease 1
Interventions
ACDN-01Drug
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of ACDN-01 as measured by the number and severity of adverse events and serious adverse events.Time frame: 12 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of San Francisco
San Francisco, California
Vitreo Retinal Associates
Gainesville, Florida
Bascom Palmer Eye Institute
Miami, Florida
Wilmer Eye Institute at John Hopkins
Baltimore, Maryland
Massachusetts Eye and Ear
Boston, Massachusetts
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Cincinnati Eye Institute
Cincinnati, Ohio
Casey Eye Institute OHSU
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Retina Foundation of the Southwest
Dallas, Texas
Retina Consultants of Texas
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.